AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLINUVEL PHARMACEUTICALS LTD

9.470

-0.190-1.97%

Volume:95.67K

Turnover:903.29K

Market Cap:475.40M

PE:14.71

High:9.600

Open:9.600

Low:9.310

Close:9.660

52wk High:13.933

52wk Low:9.310

Shares:50.20M

Float Shares:41.32M

Volume Ratio:1.19

T/O Rate:0.23%

Dividend:0.05

Dividend Rate:0.53%

EPS(TTM):0.644

EPS(LYR):0.718

ROE:13.96%

ROA:10.62%

PB:1.91

PE(LYR):13.19

Loading ...

Overview Company News Filings

Morgans says these small-cap ASX shares could rise 30% to 80%

A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results

Simply Wall St.

Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings

Simply Wall St.

BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales

Clinuvel H1 net profit after tax AUD 10.4 million -26%

BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million

Clinuvel Pharmaceuticals Ltd - Hy Revenues a$36.9 Mln

THOMSON REUTERS

Exploring 3 High Growth Tech Stocks in Australia

Simply Wall St.

Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2

MT Newswires Live

ASX Growth Companies With High Insider Ownership January 2026

Simply Wall St.

Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?

Simply Wall St.

Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential

Simply Wall St.

Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate

MT Newswires Live

Clinuvel Pharmaceuticals Says Four Patients Reported Satisfaction in Vitilgo Treatment Study

MT Newswires Live

Artrya And 2 Other High Growth Tech Stocks With Potential In Australia

Simply Wall St.

Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq

MT Newswires Live

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development

Simply Wall St.

Is Clinuvel (ASX:CUV) Using Its Singapore Peptide Hub To Quietly Redefine Its Pipeline Ambitions?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CUV.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":9.47,"timestamp":1773897120000,"preClose":9.66,"halted":0,"volume":95669,"delay":0,"changeRate":-0.019668737060041356,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"Closed","change":-0.19,"latestTime":"03-19 16:12:00 AEDT","open":9.6,"high":9.6,"low":9.31,"amount":903287,"amplitude":0.030021,"askPrice":9.56,"askSize":198,"bidPrice":9.45,"bidSize":200,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773961200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":9.66,"dividendRate":0.00528,"openAndCloseTimeList":[[1773874800000,1773896400000]],"volumeRatio":1.191674,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":9.66,"auctionPrice":9.47,"auctionVolume":11787,"auctionTime":1773897002021,"referencePrice":9.47,"referenceTime":1773912604089,"auction":3,"marketStatus":"盘后竞价","timestamp":1773897002021}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":1.191674,"shares":50200740,"dividePrice":0.05,"high":9.6,"amplitude":0.030021,"preClose":9.66,"low":9.31,"week52Low":9.31,"pbRate":"1.91","psRate":"4.94","week52High":13.933,"institutionHeld":0,"latestPrice":9.47,"committee":0.005025,"eps":0.643659,"divideRate":0.00528,"volume":95669,"delay":0,"ttmEps":0.643659,"open":9.6,"prevYearClose":12.46,"prevWeekClose":9.93,"prevMonthClose":10.01,"prevQuarterClose":12.46,"fiveDayClose":10.13,"twentyDayClose":11.71,"sixtyDayClose":13.23,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-09-05","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-09-06","defaultRemindTime":1725494400000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-20","payableDate":"2024-09-06","currency":"AUD","dateTimestamp":1725458400000,"payDate":"2024-09-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620027294","title":"Morgans says these small-cap ASX shares could rise 30% to 80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027294","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027294?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:57","pubTimestamp":1773795437,"startTime":"0","endTime":"0","summary":"Having some exposure to the small side of the market can be a good thing for a balanced portfolio, if your risk tolerance allows for it.After all, the potential returns from small-cap ASX shares can be significantly greater than those on offer with large caps.With that in mind, here are two small-cap shares that Morgans thinks could rise strongly from current levels. Let's see what it is recommending:. This biopharmaceuticals company disappointed Morgans during the first half, with softer-than-expected revenue growth and higher-than-expected cost growth.However, the broker remains positive, especially given that this small-cap ASX share trades on lower-than-normal multiples.As a result, the broker has put a speculative buy rating and $13.00 price target on its shares. This implies potential upside of 30% for investors from current levels. It said:. Whilst we downgrade our FY26-17 EBITDA forecasts by 10-20% reflecting revised guidance, given RDY's robust pipeline, potential catalysts , ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/morgans-says-these-small-cap-asx-shares-could-rise-30-to-80/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7016","CUV.AU","BK7508","RDY.AU"],"gpt_icon":0},{"id":"2618647249","title":"A Look At Clinuvel Pharmaceuticals (ASX:CUV) Valuation After Softer Half Year Earnings Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647249?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:20","pubTimestamp":1773015634,"startTime":"0","endTime":"0","summary":"Why Clinuvel’s latest half year result has caught investor attention\nClinuvel Pharmaceuticals (ASX:CUV) has drawn fresh interest after reporting half year earnings to 31 December 2025, with revenue of A$40.56 million and net income of A$10.44 million, both below the prior period.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nAt a share price of A$10.16, Clinuvel’s recent half year result lands against a backdrop of weaker momentum, with a 30 day share price return of 8.14% and a 90...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/a-look-at-clinuvel-pharmaceuticals-asxcuv-valuation-after-so","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU"],"gpt_icon":0},{"id":"2617599594","title":"Clinuvel Pharmaceuticals announces investor webinar release for the six months ended 31 December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2617599594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617599594?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:48","pubTimestamp":1772678913,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals Limited announced the availability of an investor and analyst webinar  discussing its financial results for the six months ended 31 December 2025, hosted at 18:00 AEDT on 26 February 2026, posted at CLINUVEL news website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL7ks45p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","XKO.AU","BK7096","LABU","XJO.AU","NHF.AU","BK7508","COH.AU","BK7113","MSB.AU","BK4588","MPL.AU","FPH.AU","IDX.AU","REG.AU","XLV","SHL.AU","CSL.AU","BK4585","BK4581","BK7089","HCAR","BK7067","XBI","BK7103","NEU.AU","XAO.AU","ANN.AU","BK7007","BK7126","RHC.AU","BK7511","BK7509","CUV.AU","SIG.AU","BK7124","MVF.AU","TLX.AU","HLS.AU","BK7501","CU6.AU"],"gpt_icon":0},{"id":"2616447918","title":"Assessing Clinuvel Pharmaceuticals (ASX:CUV) Valuation After EMA SCENESSE Approval And Half Year Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2616447918","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616447918?lang=en_us&edition=fundamental","pubTime":"2026-03-01 04:29","pubTimestamp":1772310599,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) is in focus after a key European Medicines Agency approval for year round SCENESSE use in erythropoietic protoporphyria, alongside fresh half year earnings that show revenue of A$40.56 million and net income of A$10.44 million.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nEven with the EMA approval and fresh half year numbers, sentiment around Clinuvel looks cautious. A 1 day share price return of 9.33% decline and a year to date share price return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/assessing-clinuvel-pharmaceuticals-asxcuv-valuation-after-em","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EMA","CUV.AU"],"gpt_icon":0},{"id":"2614288815","title":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2614288815","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614288815?lang=en_us&edition=fundamental","pubTime":"2026-02-27 12:54","pubTimestamp":1772168074,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clinuvel Pharma at near 9-month low; Jefferies trims PT on slower sales** Shares of drug maker Clinuvel Pharmaceuticals CUV.AX slip as much as 8.24% to A$10.130, lowest since July 8, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL6N3ZN0AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"gpt_icon":0},{"id":"2614205062","title":"Clinuvel H1 net profit after tax AUD 10.4 million -26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614205062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614205062?lang=en_us&edition=fundamental","pubTime":"2026-02-26 11:04","pubTimestamp":1772075090,"startTime":"0","endTime":"0","summary":"Clinuvel reported record December-half sales revenues of AUD 36.9 million in the six months to 31 December 2025 (+4%), with total revenue of AUD 40.6 million. Expenses rose to AUD 26.0 million , and net profit after tax fell to AUD 10.4 million , with basic earnings per share of AUD 0.21 . Cash and term deposits increased to AUD 233.0 million (+4%), and the balance sheet remained free of external borrowings. The company said higher spending reflected expansion plans and increased R&D activity, with personnel costs up 16% and clinical and non-clinical development costs up 19%. Commercial distribution expenses rose 42%, and finance and legal expenses increased 47%, primarily linked to an application to the U.S. SEC to upgrade its Level I ADRs to Level II for a NASDAQ listing. Management also highlighted preparation for larger markets in vitiligo and first entry to market for NEURACTHEL, an ACTH analogue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL1H6Ww2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2614069376","title":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614069376","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614069376?lang=en_us&edition=fundamental","pubTime":"2026-02-26 09:23","pubTimestamp":1772068995,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Posts HY Net Profit After Tax A$10.4 MillionFeb 26 (Reuters) - Clinuvel Pharmaceuticals Ltd CUV.AX:HY  NET PROFIT AFTER TAX A$10.4 MILLIONHY  REVENUES A$36.9 MILLIONFurther company coverage: CUV.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZL25Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2614050890","title":"Clinuvel Pharmaceuticals Ltd - Hy  Revenues a$36.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050890?lang=en_us&edition=fundamental","pubTime":"2026-02-26 06:56","pubTimestamp":1772060177,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL25Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2608307388","title":"Exploring 3 High Growth Tech Stocks in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2608307388","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608307388?lang=en_us&edition=fundamental","pubTime":"2026-02-04 03:06","pubTimestamp":1770145565,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a potential rebound, with shares expected to rise by over 1% following recent sell-offs, as investors anticipate the Reserve Bank of Australia's impending interest rate hike decision. In this dynamic environment, high-growth tech stocks can offer intriguing opportunities for investors seeking innovation and resilience amidst economic shifts and evolving global strategies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-pyc/pyc-therapeutics-shares/news/exploring-3-high-growth-tech-stocks-in-australia-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CGS.AU","XKO.AU","XAO.AU","PYC.AU","BK7094","BK7508","XJO.AU","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2608839722","title":"Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2","url":"https://stock-news.laohu8.com/highlight/detail?id=2608839722","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608839722?lang=en_us&edition=fundamental","pubTime":"2026-02-02 11:47","pubTimestamp":1770004022,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  anticipates the receipt of Health Canada's marketing authorization decision for its drug candidate Scenesse for the treatment of vitiligo in the second half of 2026, according to a Monday Australian bourse filing.The company also expects to report top-line preclinical results from its controlled-release liquid injectable platform candidate, VLRX-L, study in the first half, the filing said.The company's shares shed about 1% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2607545890","title":"ASX Growth Companies With High Insider Ownership January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607545890","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607545890?lang=en_us&edition=fundamental","pubTime":"2026-01-30 03:09","pubTimestamp":1769713763,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a period of uncertainty with flat trading and cautious investor sentiment following the U.S. Federal Reserve's recent decision to hold interest rates steady, attention turns to how local indices will respond to upcoming announcements from the Reserve Bank of Australia. In this environment, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those who know the business best and may offer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-high-insider-ownership-january-202-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EIQ.AU","BK7113","P1E.AU","BK7142","BK7095","3DP.AU","WZR.AU","BK7116","NWF.AU","XJO.AU","REG.AU","BK7117","BK7017","AEM.AU","BK7036","SKS.AU","BK7506","BK7067","LM8.AU","XKO.AU","BK7508","XAO.AU","AV1.AU","TTT.AU","CUV.AU","BK7093","SEA.AU","BK7016","BK7023"],"gpt_icon":0},{"id":"2604744915","title":"Does Clinuvel’s New VLRX-L Injectable Platform Shift the Long-Term Pipeline Narrative for ASX:CUV?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604744915","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604744915?lang=en_us&edition=fundamental","pubTime":"2026-01-17 01:30","pubTimestamp":1768584634,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently begun dosing in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform, marking the first formal evaluation of this next-generation delivery technology.\nThis step signals an effort to build a broader pipeline based on in-house intellectual property that could diversify the business beyond its existing treatment franchise if development progresses successfully.\nWe’ll now explore how advancing the proprietary VLRX-L...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/does-clinuvels-new-vlrx-l-injectable-platform-shift-the-long","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VLRX","CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2603545606","title":"Clinuvel Pharmaceuticals (ASX:CUV) Valuation Check As VLRX L Preclinical Milestone Expands Pipeline Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2603545606","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603545606?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:34","pubTimestamp":1768462462,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) has started dosing patients in a preclinical study of its VLRX-L controlled-release liquid injectable peptide platform. This marks its first next-generation delivery technology to enter formal preclinical testing.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe VLRX-L preclinical milestone comes as the share price sits at A$12.75, with a 1-day share price return of 4.25% and a 90-day share price return of 10.29%, while the 1-year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-as-vlrx-l-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","BK7508","BK7067","VLRX"],"gpt_icon":0},{"id":"2602810564","title":"Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2602810564","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602810564?lang=en_us&edition=fundamental","pubTime":"2026-01-12 10:08","pubTimestamp":1768183730,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  started dosing in its preclinical study with its controlled-release liquid injectable platform candidate, VLRX-L, designed to control the release of peptides, according to a Monday Australian bourse filing.The study seeks to evaluate the controlled-release profile of VLRX-L candidates and determine the reproducibility of drug release using an in-vitro model, the filing said.The company seeks to complete the preclinical program in the second half of 2026.Clinuvel Pharmaceuticals' shares rose almost 2% in recent trading on Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","CUV.AU"],"gpt_icon":0},{"id":"2601387517","title":"Clinuvel Pharmaceuticals Says Four Patients Reported Satisfaction in  Vitilgo Treatment Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2601387517","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601387517?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:44","pubTimestamp":1767829487,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  said four patients with darker skin types enrolled in its study of drug candidate Scenesse in the treatment of vitiligo reported satisfaction with the treatment, which was also well tolerated, according to a Thursday filing with the Australian bourse.The patients had received seven implants of the drug candidate and up to 40 adjunct narrowband ultraviolet B phototherapy sessions, the filing said.Shares of the company rose 2% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","CUV.AU"],"gpt_icon":0},{"id":"2601420837","title":"Artrya And 2 Other High Growth Tech Stocks With Potential In Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2601420837","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601420837?lang=en_us&edition=fundamental","pubTime":"2026-01-06 03:06","pubTimestamp":1767639983,"startTime":"0","endTime":"0","summary":"As the Australian market kicks off 2026, the ASX has been relatively flat with a brief pause in the Santa Rally, while IT stocks have led declines amidst broader market uncertainties. In this environment, identifying high-growth tech stocks like Artrya and others requires careful consideration of their potential to navigate current challenges and capitalize on emerging opportunities within Australia's dynamic economic landscape.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice1-main-header/1585186828574"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/artrya-and-2-other-high-growth-tech-stocks-with-potential-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-cgs/cogstate-shares/news/artrya-and-2-other-high-growth-tech-stocks-with-potential-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7094","XAO.AU","XKO.AU","CUV.AU","XJO.AU","AYA.AU","BK7508","CGS.AU","BK7067"],"gpt_icon":0},{"id":"2592135240","title":"Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2592135240","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592135240?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:23","pubTimestamp":1766107403,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals  filed a draft registration statement with the US Securities and Exchange Commission , seeking to uplist its American depositary receipt  program on the Nasdaq Stock Market to Level II from Level I, according to a Friday Australian bourse filing.Around 25% of the firm's issued capital is currently held by US-based investors, the filing noted. If approved, its ADR is expected to trade on Nasdaq with the ticker \"CLVL.\"The submission of the draft registration statement, including the Form 20-F annual report, is necessary for the SEC to recognize a non-US company as a \"Foreign Private Issuer\" and list securities on US stock exchanges. After the initial filing, the SEC will review the registration statement and provide feedback within a 30-day window.Its shares rose over 2% in recent trading on Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ADR.AU","BK4117","BK7094","BK4107","BK7508","CUV.AU","SEC.AU","AFG","NQmain"],"gpt_icon":0},{"id":"2590554975","title":"Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2590554975","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590554975?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:15","pubTimestamp":1765401311,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development.\nSee our latest analysis for Clinuvel Pharmaceuticals.\nThe market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-after-vallau","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/clinuvel-pharmaceuticals-asxcuv-valuation-check-after-vallau","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CUV.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2590314785","title":"Is Clinuvel (ASX:CUV) Using Its Singapore Peptide Hub To Quietly Redefine Its Pipeline Ambitions?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590314785","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590314785?lang=en_us&edition=fundamental","pubTime":"2025-12-09 17:15","pubTimestamp":1765271759,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals has recently expanded its Vallaurix research, development, and innovation hub in Singapore, backed by the Singapore Economic Development Board, to build a global center for advanced, long-acting peptide therapies and integrated formulation and analytical sciences.\nThis move strengthens Clinuvel’s push toward greater vertical integration in peptide-based medicine, aiming to speed up late-stage development programs and broaden its pipeline beyond a single flagship...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/is-clinuvel-asxcuv-using-its-singapore-peptide-hub-to-quietl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/is-clinuvel-asxcuv-using-its-singapore-peptide-hub-to-quietl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0031619046.USD","IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK7067","CUV.AU","BK7508","HUBG","BK4131"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}